Do your job with all your heart
Release time:
2021-03-01
Pharmaceutical Company 2020 Outstanding Marketer Pharmaceutical Sales Company Jinhua Office Shao Junli
Looking back on 2020 , all of us will be deeply touched. The new coronavirus epidemic is raging and spreading, and the whole country will make the fight against the epidemic a top priority. Especially at the beginning of the year, we are familiar with the words "city ", "road ", "isolation " and "home " . we dare not go out easily, let alone go to the hospital - where the virus is most subconscious, therefore, our salesman is very worried about whether the task can be completed in the first quarter. We know that the hospital has the most viruses and is also the most dangerous place, but I am still taking self-protection measures and comforting myself "The most dangerous place is also the safest place " Visit the customer in the hospital, ask the customer what help he needs, and do his best to get the job done. At the same time, the national centralized procurement was carried out in major hospitals in an orderly manner. Our Paro was returned to the original market. We could only fill the sales volume with strength. Under such difficult circumstances, all colleagues in our Jinhua office exceeded the sales target and handed in satisfactory answers.
It has been 6 years since I joined the peak job. In fact, I have not made any earth-shattering contribution or outstanding achievements worth showing off. What I have done is to do every job in my post with all my heart, to do my best and ability to complete every task index, to sum up experience in time, to reflect on work all the time and to learn lessons, ask colleagues or leaders in time if you don't understand anything to improve work efficiency. I firmly believe that as long as you work diligently, do every job well, and complete every task in a round and full manner, you will definitely get the rewards you deserve.
What impressed me most was that when I just took over the service station of Yunshan Street Health Center in Lanxi City, the sales volume of the whole health station was only ,400 boxes per month. After handing over the market with my colleagues, I focused my work on the quantity of the station, because I knew very well that the development of hierarchical diagnosis and treatment system would make primary health centers the core market of chronic disease drugs, therefore, I must be careful and strong in grass-roots health centers. First of all, I inquired about several sites under the hospital. After understanding, I visited each site frequently, increased support for the work of each webmaster, and improved customers' awareness of peak products. After a year of work accumulation, the sales volume of each site rose sharply every month. At present, the sales volume of Lest in Yunshan Street Health Center can reach 2000 boxes per month. In the second half of the year, I also successfully developed Olo into Yangbu Health Center and Lanxi Hospital of Traditional Chinese Medicine.
can be rated as an excellent salesman. This is the affirmation and praise of the pharmaceutical company for my personal work ability and achievements. It is also an encouragement to me to do my job well in the future, and it is also a spur to my future work. The achievements belong to the past, and the challenges of the new year have begun. In order to complete the development goals and tasks of 2021 , let's cheer together.
(according to Shao Junli's speech at the summary and commendation meeting of the pharmaceutical company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page